CANDEL THERAPEUTICS INC. - COMMON STOCK

Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

06 дек 2022 15:26:35 Источник Nasdaq GlobeNewswire

Candel Therapeutics to Host Virtual R&D Day on December 6, 2022

29 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

18 ноя 2022 07:00:00 Источник Nasdaq GlobeNewswire

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

11 ноя 2022 11:00:00 Источник Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

10 ноя 2022 07:00:03 Источник Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO

07 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Candel Therapeutics Upcoming Investor Conference Participation for November

01 ноя 2022 07:00:03 Источник Nasdaq GlobeNewswire

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

26 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

15 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Candel Therapeutics Announces Two Executive Leadership Appointments

07 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

Candel Therapeutics Upcoming Investor Conference Participation

06 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

05 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

26 май 2022 16:30:00 Источник Nasdaq GlobeNewswire

Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

18 май 2022 07:00:01 Источник Nasdaq GlobeNewswire

Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

12 май 2022 07:00:02 Источник Nasdaq GlobeNewswire

Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

27 апр 2022 15:00:00 Источник Nasdaq GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights

29 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer

02 мар 2022 07:00:02 Источник Nasdaq GlobeNewswire

Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank

01 мар 2022 07:00:02 Источник Nasdaq GlobeNewswire

Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

03 фев 2022 07:00:01 Источник Nasdaq GlobeNewswire